Back to article: Therapeutic anti-tumor immunity directed against neo-epitopes by intratumor delivery of mRNA encoding MLKL

FIGURE 1: Proposed therapeutic mechanism of intratumor treatment with mRNA encoding MLKL. 1. In vitro transcribed hypo-inflammatory mRNA encoding MLKL is injected in an established tumor followed by electroporation. 2. MLKL-mRNA can enter cells in the tumor mass and evoke cell death with necroptotic hallmarks. Necroptotically dying cells release alarm signals that attract immune cells. 3. DCs are attracted to the dying tumor cells and will take up tumor-specific antigens and subsequently cross-present these in the draining lymph node (LN) to CD4+ and CD8+ T cells. 4. These resulting tumor neo-antigen-specific CD4+ and CD8+ T cells can than eliminate the treated as well as distal untreated tumors.

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this. Please refer to our "privacy statement" and our "terms of use" for further information.